Relapsed/Refractory

Criteria to qualify for study: Drug used in study:
  • ECOG <= 2; diagnosis of classical Hodgkin Lymphoma

LYM 157

A phase 2 front line PET/CT -2 response adapted Brentuximab Vedotin and Nivolumab incorporated and Radiation free management of early stage Classical Hodgkin Lymphoma (Chl)